A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
Clinical trial NCT05714202 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05714202
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-23
- Primary completion
- 2029-09-18
- Enrollment
- 1135
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.